Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of MRA and SGLT2 inhibitor withdrawal to maintain remission in dilated cardiomyopathy
ISRCTN60045220Phase 4Active, not recruiting
- Sponsor
- Imperial College London
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of canrenoic acid in dilated cardiomyopathy (DCM) (2 arms), sponsored by Imperial College London. Primary endpoint: Relapse of dilated cardiomyopathy. Started Oct 2023; status: active, not recruiting.
02
Drugs
canrenoic acid
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on ISRCTN60045220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN60045220.